Please login to the form below

Not currently logged in

J&J sells Cordis unit to Cardinal Health for $1.94bn

Johnson and Johnson logoMarks J&J’s exit from the cardiovascular stent market

Complaints about UK medical advertising drop

mhra logoAnd this year the MHRA will be vetting adverts to promote a ‘right first time’ approach

GSK public-private partnership CTTV names director

Centre for Therapeutic Target Validation launched last year

Novartis divests cancer drugs to bring GSK deal to completion

Array BioPharma picks up the Swiss companny's BRAF and MEK inhibitors

Amgen's Kyprolis tops Velcade in myeloma trial

Amgen flagAmgen hoping to topple Takeda’s $2bn a year drug

Sanofi’s Lantus follow-up nears European approval

Sanofi receptionCHMP backing for Toujeo follows hot on the heels of its US approval by the FDA

Greater Manchester to control its share of the NHS budget

UK flagThe north-west English region accounts for 5% of the country's health spending

Jinarc backed for European approval in rare kidney disease

EU flagPositive opinion for Otsuka comes just before rare disease awareness day

darwins medicineDoes 'trust leadership' feature in your strategy?

Pharma companies wanting to be more patient-focused will need to develop their people skills

Latest appointments

Featured jobs

Subscribe to our email news alerts


Add my company
Red Door Unlimited

Red Door Unlimited is the health and wellbeing communications consultancy that lives and breathes originality and is built on `firsts'....

Latest intelligence

Growing influence of pharmacists in the sale of Rx and OTC medicines
Find out how the changes within pharmacy have affected their influence over the sales of RX and OTC medicines in this whitepaper....
Drivers of 2014′s Soaring Drug Approvals
The FDA & EMA approved a chart-topping number of new drugs in 2014. Read more in our White Paper about the responsibility this growing approval success will put on future...
Russian innovation at the crossroads
Despite improvements, investors face rising risks...